Researchers at Johns Hopkins Medicine have identified the gene KLF5 as a pivotal factor in the metastasis of pancreatic cancer, revealing that it operates not through DNA mutations but by rewiring gene expression via epigenetic mechanisms. This study highlights KLF5’s role in promoting tumor growth and invasion, particularly in metastatic cells, and underscores its influence on the regulation of other genes associated with cancer progression.

The findings are significant as they challenge the traditional understanding of cancer metastasis, which often emphasizes genetic mutations. Instead, KLF5’s activity appears to drive epigenetic alterations that dictate gene activation and silencing, thereby facilitating the spread of cancer. In patient samples, KLF5 was found to be upregulated in 10 out of 13 metastatic tumors compared to their primary counterparts. This suggests that targeting KLF5 and its regulatory pathways could offer a novel therapeutic avenue for treating pancreatic cancer, particularly in its advanced stages.

The implications of this research extend to drug development, as it shifts the focus towards epigenetic therapies that modulate KLF5 activity rather than completely inhibiting it. Current experimental drugs targeting KLF5 are already in development, suggesting a potential for more effective treatments that could improve patient outcomes by addressing the underlying mechanisms of metastasis. This study not only enhances our understanding of pancreatic cancer biology but also opens new avenues for therapeutic strategies that could alter the course of this aggressive disease.

Source: sciencedaily.com